Syndrome News and Research

RSS

Study observes neurological and psychiatric outcomes in recovered COVID-19 patients six months post-infection

A new study by researchers at Oxford University examines neurological and psychiatric outcomes in recovered COVID-19 patients six months post-infection.

15 Apr 2021

Future attempts to reduce Covid-19 spread should focus on tackling airborne transmission

Any future attempts to reduce the spread of covid-19 should be focused on tackling close airborne transmission of the virus which is considered to be the primary route for its circulation, according to experts in an editorial published in The BMJ.

15 Apr 2021

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

A new study by researchers in Jerusalem indicates that while specific antibodies to the virus are present in both serum and ovarian follicles following infection or vaccination, there is no apparent adverse effect on follicular function as a result.

15 Apr 2021

High antibody and inflammatory mediator levels may predict severe COVID-19

A new study reports on biomarkers could help predict the progression of the viral illness to dangerous levels early enough to enable timely intervention.

15 Apr 2021

Allometric model shows human travel is closely related to spread of COVID-19

A new study indicates that the spread of COVID-19 is governed by power-law dynamics, suggesting that alternative modeling approaches need to be used to understand and predict its propagation.

15 Apr 2021

More than half of COVID-19 patients report persistent symptoms 12-months after infection

In a new study, appearing on the pre-print server medRxiv*, researchers at the University of Trieste and Istituto Auxologico Italiano IRCCS in Italy report that more than half of patients with previous mild-to-moderate symptomatic COVID-19 complained of the persistence of at least one symptom 12-months after the onset of the illness.

15 Apr 2021

COVID-19 deadlier than cars for over 40s, study finds

The study, which appeared on the pre-print server medRxiv, presented mortality rates and case-fatality rates for COVID-19 compared with other historic leading causes of death in the United States.

15 Apr 2021

Speed of vaccination is key to reducing COVID-19 spread, says study

Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.

15 Apr 2021

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

A new study published ahead of print in the Clinical Chemistry and Laboratory Medicine (CCLM) journal reports the production of a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the Pfizer-BioNTech BNT162b2 vaccine. The increase in humoral immunity includes elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels after the second mRNA dose.

14 Apr 2021

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

14 Apr 2021

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

Researchers in the United States have predicted the binding epitopes of uncharacterized neutralizing antibodies that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

14 Apr 2021

Early monoclonal antibody therapies beneficial for COVID-19, finds study

A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.

14 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

The study, published in The Lancet, demonstrates that there is no evidence of a link between severe illness and death and lineage when comparing the B.1.1.7 lineage and other variants.

14 Apr 2021

Risk of E.R. visit or hospitalization 82% lower in mAbs-treated SARS-CoV-2 patients: Study

Recently, researchers from the U.S. reviewed electronic health records of SARS-CoV-2 patients at a medical center that started mAb infusions in January 2021 with the support of the National Disaster Medical System, part of the U.S. Department of Health and Human Services. The study is published on the preprint server, medRxiv.

14 Apr 2021

Experimental evidence that ADAM17 inhibition prevents severe COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that is contagious in humans. It is the causal agent of the ongoing coronavirus 2019 (COVID-19) pandemic. This virus causes a mild to severe infection and has claimed over 2.95 million lives worldwide. SARS-CoV-2 is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.

13 Apr 2021

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

The spike protein is the main part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the infection. It consists of two subunits S1 and S2. Upon entry of the virus into the human body, the S1 subunit helps the virus bind to the angiotensin-converting enzyme 2 (ACE2) receptors on host cells.

13 Apr 2021

Syndrome News and Research

Study observes neurological and psychiatric outcomes in recovered COVID-19 patients six months post-infection

Future attempts to reduce Covid-19 spread should focus on tackling airborne transmission

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

High antibody and inflammatory mediator levels may predict severe COVID-19

Allometric model shows human travel is closely related to spread of COVID-19

More than half of COVID-19 patients report persistent symptoms 12-months after infection

COVID-19 deadlier than cars for over 40s, study finds

Speed of vaccination is key to reducing COVID-19 spread, says study

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

Early monoclonal antibody therapies beneficial for COVID-19, finds study

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

Risk of E.R. visit or hospitalization 82% lower in mAbs-treated SARS-CoV-2 patients: Study

Experimental evidence that ADAM17 inhibition prevents severe COVID-19

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News